About Oncquest Laboratories Limited
Data last updated: 06 February 2026
Oncquest Laboratories Limited is a public limited company based in New Delhi, Delhi, India, a subsidiary of Milky Investment & Trading Co. It specialises in diagnostic centers and pathology labs, a part of the broader healthcare sector. Incorporated on 29 November 2007, the company has been in operation for over 19 years.
Registered with ROC Delhi under CIN U24233DL2007PLC170898.
Capital: an authorised share capital of ₹38 Cr and a paid-up capital of ₹38 Cr. Formerly known as Oncquest Laboratories Private Limited. It is led by directors including Aditya Chand Burman and Rajiv Kapoor.
Last AGM: 29 September 2025. Financial statements filed for year ended 31 March 2025. Office: First Floor Ashi 19 Rouse Avenue Institutional Area, New Delhi, Delhi, India – 110002.
As per the financials filed for FY 2025, the company reported a revenue of ₹97.99 Cr, a growth of 0% compared to the previous year.
The company has a workforce of approximately 739 employees as per the latest available data. It operates as a subsidiary of Milky Investment & Trading Co.
The company is associated with 2 brands - Oncquest, Oncquest Laboratories.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website oncquest.net.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressFirst Floor Ashi 19 Rouse Avenue Institutional Area, New Delhi, Delhi, India – 110002
-
IndustryHealthcare, Diagnostic Centers & Pathology Labs
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Oncquest Laboratories Limited
Oncquest Laboratories Limited has one previous CIN (Corporate Identification Number): U24233DL2007PTC170898. The current CIN is U24233DL2007PLC170898, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24233DL2007PLC170898 | Current |
| U24233DL2007PTC170898 | Previous |
Associated Brands with Oncquest Laboratories Limited
Oncquest Laboratories Limited operates two associated brands: Oncquest and Oncquest Laboratories. These brands represent Oncquest Laboratories Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Operates a chain of pathology laboratory centers providing diagnostic services. | oncquestlabs.com | |
| Chain of diagnostic labs | oncquest.net |
Competitors & Alternatives of Oncquest Laboratories Limited
Brands and companies operating in the same space as Oncquest Laboratories Limited include Dr Lal PathLabs, Redcliffe Labs, Metropolis India and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Dr Lal PathLabs
|
Chain of pathology and radiology labs | Gurugram, India, India | 1949 |
Redcliffe Labs
|
Home-based diagnostic tests are booked via an online platform. | Noida, India, India | 2018 |
Metropolis India
|
Diagnostic centers are operated as a nationwide chain. | Mumbai, India, India | 1981 |
Orange health
|
At-home diagnostic tests are booked and collected by phlebotomists. | Bengaluru, India, India | 2020 |
Agilus Diagnostics
|
Leading diagnostic chain providing quality blood test and full body checkup services | Gurugram, India, India | 1995 |
Apollo Diagnostics
|
Provides pathology lab tests, health check packages, and home sample collection. | Hyderabad, India, India | 2015 |
Sterling Accuris Diagnostics
|
Pathology diagnostic services are offered via a chain of labs. | Ahmedabad, India, India | 2015 |
Airmed
|
Provider of a chain of diagnostic labs | Ahmedabad, India, India | 2016 |
Business Activity of Oncquest Laboratories Limited
Oncquest Laboratories Limited is engaged in the principal business activity of hospital and medical care, with detailed activities including other hospital and medical care activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q6 | Other Hospital and Medical Care Activities | ********* |
Auditor Details of Oncquest Laboratories Limited
Oncquest Laboratories Limited is audited by T R Chadha & Co LLP for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| T R Chadha & Co LLP | blur-value | blur-value | blur-value |
Board of Directors of Oncquest Laboratories Limited
Oncquest Laboratories Limited is currently managed by 6 directors, with 23 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Aditya Chand Burman
Also directs:
Dabur India Limited, Eveready Industries India Ltd, A.Cee Enterprises (A Private Company With Unlimited Liability) and 2 more
|
Director | 29 Nov 2007 | 18 Years 7 Months | Current |
| Rajiv Kapoor | Director | 23 Jan 2024 | 2 Years 5 Months | Current |
|
Gaurav Chamaria
Also directs:
Blackburrow Agritech Private Limited, Dabur Pharmaceutical Ltd, Super Hoze Industries Private Limited and 5 more
|
Director | 26 Oct 2023 | 2 Years 8 Months | Current |
| Naresh Chander Arora | Director | 16 May 2025 | 1 Years 1 Months | Current |
Financials of Oncquest Laboratories Limited FY 2025 filings available
Oncquest Laboratories Limited reported revenue of ₹97.99 Cr (up 0% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Oncquest Laboratories Limited
As of FY 2023, Oncquest Laboratories Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Oncquest Laboratories Limited
Oncquest Laboratories Limited has 1 associated company. This group structure data is as of FY 2023. The corporate group structure reflects Oncquest Laboratories Limited's business expansion strategy and organizational complexity.
Charges & Borrowings Oncquest Laboratories Limited
Oncquest Laboratories Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Oncquest Laboratories Limited
Oncquest Laboratories Limited has a workforce of 739 employees as of Nov 08, 2024.
Employee Count & EPFO Data of Oncquest Laboratories Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Oncquest Laboratories Limited
GSTIN & GST Filing Data of Oncquest Laboratories Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Oncquest Laboratories Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Oncquest Laboratories Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Oncquest Laboratories Limited
MSME Payment Delays by Oncquest Laboratories Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Oncquest Laboratories Limited
Subsidiaries & Group Companies of Oncquest Laboratories Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Oncquest Laboratories Limited with ownership details.
MCA Filings & Documents of Oncquest Laboratories Limited
MCA Filings & Documents of Oncquest Laboratories Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Oncquest Laboratories Limited
Recent News on Oncquest Laboratories Limited
Frequently Asked Questions about Oncquest Laboratories Limited
Oncquest Laboratories Limited is an active public limited company in the healthcare sector based in New Delhi, Delhi, India. It was incorporated on 29 November 2007 (19+ years old) and is registered under CIN U24233DL2007PLC170898. The company has 739 employees.
Oncquest Laboratories Limited reported revenue of ₹97.99 Cr for FY 2025 (up 0.00% YoY).
The current directors of Oncquest Laboratories Limited are:
- Aditya Chand Burman
- Rajiv Kapoor
- Vandana Wadhwa
- Gaurav Chamaria
- Naresh Chander Arora
- Swati Rawat
The primary industry of Oncquest Laboratories Limited is healthcare. The company specifically operates in diagnostic centers and pathology labs. The company is currently active in this sector.
Oncquest Laboratories Limited can be reached at the registered office: First Floor Ashi 19 Rouse Avenue Institutional Area, New Delhi, Delhi, India – 110002, or through the website oncquest.net.
The authorised capital is ₹38 Cr, and the paid-up capital is ₹38 Cr.